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A B S T R A C T
Cell-free permeation systems are gaining interest in drug discovery and development as tools to obtain a reliable
prediction of passive intestinal absorption without the disadvantages associated with cell- or tissue-based per-
meability proﬁling. Depending on the composition of the barrier, cell-free permeation systems are classiﬁed into
two classes including (i) biomimetic barriers which are constructed from (phospho)lipids and (ii) non-biomi-
metic barriers containing dialysis membranes. This review provides an overview of the currently available cell-
free permeation systems including Parallel Artiﬁcial Membrane Permeability Assay (PAMPA), Phospholipid
Vesicle-based Permeation Assay (PVPA), Permeapad®, and artiﬁcial membrane based systems (e.g. the artiﬁcial
membrane insert system (AMI-system)) in terms of their barrier composition as well as their predictive capacity
in relation to well-characterized intestinal permeation systems. Given the potential loss of integrity of cell-based
permeation barriers in the presence of food components or pharmaceutical excipients, the superior robustness of
cell-free barriers makes them suitable for the combined dissolution/permeation evaluation of formulations.
While cell-free permeation systems are mostly applied for exploring intestinal absorption, they can also be used
to evaluate non-oral drug delivery by adjusting the composition of the membrane.
1. Introduction
Despite the tremendous increase in approved (bio)pharmaceutical
products intended for intravenous or subcutaneous administration, the
oral route of administration remains of major interest since it is bene-
ﬁcial from an economical, convenience and safety point of view (“2016
FDA drug approvals - nrd.2017.14.pdf,” n.d.; Ecker et al., 2014).
Nevertheless, before reaching the systemic circulation and, subse-
quently, its site of action, the orally administered drug must cross the
intestinal mucosa, a major barrier for oral drug delivery.
Numerous methods exist to estimate the extent of absorption across
the human gastrointestinal wall (Bohets et al., 2001; Buckley et al.,
2012). Using a fairly simple computational approach, diﬀerent research
groups proposed to estimate drug permeation based on physicochem-
ical drug properties including molecular weight (MW), lipophilicity
(log D), acid dissociation constant (pKa), polar surface area (PSA), and
hydrogen bonding potential (Camenisch et al., 1998; Neuhoﬀ et al.,
2005; Palm et al., 1997; Veber et al., 2002). These molecular
descriptors, with the exception of pKa and PSA, are well covered in
Lipinski's rule of 5 and provide a rational basis for understanding oral
drug absorption processes in early stage drug development (Lipinski
et al., 2001; Veber et al., 2002).
In contrast to this over-simpliﬁcation of estimating intestinal drug
permeation, tissue-based permeation models oﬀer the advantage to
closely mimic the in vivo situation from an anatomical, biochemical and
structural point of view. For instance, the in situ rat intestinal perfusion
technique with mesenteric blood sampling is often used for speciﬁc
research scenarios aiming at (i) unravelling intestinal drug absorption
mechanisms induced by drug transporters and cytochrome P450 en-
zymes allowing the investigation of transporter-metabolism interac-
tions and (ii) exploring diﬀerences in regional drug absorption
(Stappaerts et al., 2015; Ungell et al., 1998). Alternatively, the Ussing
chambers model, in which rat or human intestinal tissue is mounted
between 2 half chambers, also oﬀers the opportunity to investigate
diﬀerences in regional drug absorption, carrier-mediated transport and
the impact of intestinal metabolism on drug transport (Mols et al.,
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2005; Rogers et al., 1987). Despite their high relevance for the in vivo
situation, these tissue-based absorption systems are associated with
several drawbacks including low- to moderate-throughput, limited
tissue availability, ethical burdens and challenging experimental pro-
cedures. More speciﬁc drawbacks, which further impede the use of
tissue-based permeation models, are the unknown eﬀect of anesthesia
on drug absorption using the in-situ perfusion method and the possible
underestimation of drug transport due to accumulation in the irremo-
vable circular muscle layers in the Ussing chambers model.
Cell-based systems including the human colorectal adenocarcinoma
(Caco-2) cell line and the Madin Darby canine kidney (MDCK) cell line
are considered as valuable alternatives to assess intestinal drug per-
meation. In particular, the well-established Caco-2 cell line is widely
used since this system generates reproducible and biorelevant perme-
ability results on a high-throughput basis (Balimane et al., 2000). The
presumed superior predictive power of cell-based models over mole-
cular descriptors depends on careful selection of a reference compound
set (Linnankoski et al., 2008). Furthermore, this permeation model al-
lows for the investigation of carrier-mediated transport due to the ex-
pression of intestinal uptake and eﬄux transporters (Matsson et al.,
2015; Ölander et al., 2016). Despite their high popularity, cell-based
permeation systems suﬀer from several shortcomings including a re-
lative incompatibility with food components and certain pharmaceu-
tical excipients, the absence of CYP3A4 and the lack of a mucus layer
(Sun et al., 2002). Furthermore, large inter- and intra-laboratory
variability in transporter expression may impair comparability of the
measured permeability values (Hayeshi et al., 2008; Lee et al., 2017).
Despite the reasonable predictive power of tissue- and cell-based
permeation systems for the estimation of intestinal drug permeation,
these models suﬀer from time-consuming and expensive preparation
steps. As a result, a growing interest in the development of cell-free
permeation systems has evolved wherein lengthy and expensive pre-
paration steps are drastically reduced.
The present review provides an overview of the currently available
cell-free permeation systems including the parallel artiﬁcial membrane
permeation assay (PAMPA), the phospholipid vesicle based permeation
assay (PVPA), Permeapad® and the artiﬁcial membrane insert system
(AMI-system). The main focus of this review is the description of these
permeation systems in the context of oral drug delivery; however, a
section on their applicability in non-oral drug delivery evaluation is
also included.
2. Mechanisms of intestinal drug absorption
While drug absorption in the stomach is of minor importance, the
small intestine is the main site of absorption of orally administrated
drugs due to its unique anatomical properties. Particularly, the presence
of (micro)villi drastically increases the surface area of the intestinal
mucosa resulting in the enormous absorptive surface area of the small
intestine (Helander and Fändriks, 2014; Niess and Reinecker, 2006).
Drugs can cross the intestinal epithelium layer in several ways, as il-
lustrated in Fig. 1. The type of intestinal transport is strongly connected
to several physicochemical properties of the drug as described by Li-
pinski's rule of ﬁve which indicates whether a drug is likely to be ab-
sorbed after oral administration (Lipinski, 2000; Lipinski et al., 2001).
For instance, depending on the lipophilicity of the drug, passive diﬀu-
sion through the enterocytes (transcellular diﬀusion, Fig. 1(A)) is the
preferred route for lipophilic compounds, while small hydrophilic
compounds are mainly absorbed via passive diﬀusion between the en-
terocytes (paracellular diﬀusion, Fig. 1(B)) (Artursson et al., 1993;
Camenisch et al., 1996). However, the contribution of passive para-
cellular diﬀusion to the overall drug transport is limited since the area
available for this type of transport only accounts for 0.01% of the total
surface area of the intestinal membrane (Zhu et al., 2017). In contrast to
these passive routes of transport, some drugs reach the systemic cir-
culation by means of active uptake (Fig. 1(C)), which requires energy
(Tsuji and Tamai, 1996). As a result of this energy-dependence, active
transport enables drug transport against a concentration gradient. Ad-
ditionally, eﬄux transporters (Fig. 1(D)) limit intestinal drug absorp-
tion by actively transporting drugs back to the luminal environment
(Chan et al., 2004; Kapitza et al., 2007). Finally, transcytosis, i.e.
compounds migrating from the luminal to the serosal side of the in-
testinal epithelium layer by incorporation in vesicles from the cell
membrane, may contribute to the uptake of certain drugs (Fig. 1(E))
(Florence and Hussain, 2001).
In the past decades, the majority of new chemical entities (NCEs) in
the pipeline of pharmaceutical companies have increased in lipophili-
city and size; as a result, many of these NCEs are preferably absorbed by
passive transcellular diﬀusion (Fig. 1(A)). Presently, 80%–95% of the
commercially available drugs are mainly absorbed transcellularly
(Mandagere et al., 2002), justifying the development of time-and cost-
eﬀective cell-free permeation systems. It should be noted, however, that
these cell-free permeation tools could be exclusively applied for pre-
dicting passive transcellular drug transport; paracellular and active
drug transport cannot be captured.
3. Currently available cell-free permeation systems and their
predictive capacity
Depending on the composition of the barrier, cell-free permeation
systems are typically classiﬁed into two classes including (i) biomimetic
barriers which are constructed from (phospho)lipids and (ii) non-bio-
mimetic barriers containing dialysis membranes. Below, an overview of
the currently available cell-free permeation systems is provided in
terms of their barrier composition. In addition, their predictive capacity
is discussed in relation to well-characterized permeation systems.
3.1. Parallel artiﬁcial membrane permeation assay (PAMPA)
3.1.1. Original PAMPA
In 1998, PAMPA was introduced for the ﬁrst time when the Roche
team presented the use of artiﬁcial membranes in a 96 well microtiter
plate format, as illustrated in Fig. 2 (Kansy et al., 1998). PAMPA bar-
riers generally consist of a ﬁlter (e.g. polyvinylidene ﬂuoride (PVDF))
soaked with (phospho)lipids dissolved in an organic solvent. Since the
PAMPA barrier does not contain a physical boundary separating the
donor media from the lipophilic barrier constituents, potential dis-
solution/emulsiﬁcation of barrier constituents into the media may
occur. Initially, an n-dodecane solution of egg lecithin (1–20%) (a
mixture of lipids containing phosphatidylcholine, phosphatidylethano-
lamine, phosphatidylinositol, and cholesterol) was used to mimic the
phospholipid composition of the mammalian membrane. Using this
composition, Kansy and co-workers were able to correlate measured
PAMPA ﬂuxes at diﬀerent pH values (6.5 and 7.4) with the fraction
absorbed in humans (Kansy et al., 1998). Although the relationship
obtained between the measured permeability values and the fractions
absorbed in humans was similar to what was described for Caco-2
permeation studies, PAMPA suﬀers from the inability to predict para-
cellular and active transport, and potential membrane retention of li-
pophilic compounds. However, the contribution of paracellular trans-
port to overall drug transport can be addressed using additional in silico
models, which simulate the characteristics of the human epithelium;
this approach may avoid underestimation of the fraction absorbed of
small, hydrophilic molecules like atenolol, metformin, cimetidine or
terbutaline (Adson et al., 1994; Sugano et al., 2002).
3.1.2. Variants of PAMPA
In the following years, several variations of the setup were pub-
lished, which reﬂect tissues in the human body containing diﬀerent
lipid compositions (Proulx, 1996). The variants of the original PAMPA
assay, which are listed in Table 1, diﬀer by the nature of the ﬁlter
support, the composition of the membrane constituents, the pH in
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donor/acceptor, and the presence of a “sink” in the acceptor compart-
ment (Faller, 2008). Since the (phospho)lipids and the organic solvent
can be adjusted within certain limits according to the speciﬁc appli-
cation, it is plausible that the compatibility of PAMPA barriers with co-
solvents, excipients and biomimetic media may vary according to the
composition of the barrier which is further discussed in Section 4.1. The
incorporation of phospholipids modiﬁes the physicochemical properties
of the alkane solution and, as a result, aﬀects the membrane perme-
ability as well as the membrane retention properties. For example, in
the PAMPA models described by Sugano et al. and Zhu et al., a rela-
tively low concentration of (phospho)lipids is used (Sugano et al., 2001;
Zhu et al., 2002). While the ﬁrst approach aimed to consider para-
cellular transport (Sugano et al., 2001), the second approach used a
hydrophilic PVDF ﬁlter (instead of a hydrophobic PVDF ﬁlter) as sup-
porting barrier to reduce the transport time signiﬁcantly (Zhu et al.,
2002). In contrast, the (phospho)lipid concentration is increased in the
Double-Sink™ PAMPA (PAMPA-DS) model consisting of a PVDF ﬁlter
impregnated with 20% lecithin in n-dodecane. As the name indicates,
the PAMPA-DS model employs both a pH-gradient and a ‘sink’ created
by the addition of a surfactant or serum proteins to the acceptor
medium which is beneﬁcial with regard to the assessment of poorly
water soluble drugs (Avdeef, 2005). The use of a surfactant containing
acceptor medium suggests that PAMPA-DS possesses an intrinsic re-
sistance against surfactants.
3.2. Phospholipid vesicle-based permeation assay (PVPA)
3.2.1. Original PVPA
The PVPA, which is depicted in Fig. 3, was introduced in 2006 by
the University of Tromsø as a new artiﬁcial liposome based in vitro
model representative for the intestinal epithelium intended for the es-
timation of passive drug permeability (Flaten et al., 2006b). The con-
cept was that the building blocks (i.e. liposomes) of this permeation tool
closely mimic the phospholipid bilayer of the intestinal cell membrane
from a structural point of view. When depositing a tight barrier of
liposomes on a ﬁlter support, the obtained barrier could be considered
as a valuable substitute for the intestinal epithelium (Flaten et al.,
2006b). The original PVPA consists of egg phospholipids, mainly
phosphatidylcholine, a component found in the intestinal epithelia as
well as in many other biological absorption barriers (Naderkhani et al.,
2014a).
It has been reported that the apparent permeability coeﬃcients
(Papp) obtained from the PVPA correlate well with literature data on the
human fraction absorbed. More speciﬁcally, when dividing drugs into
three categories including (i) poor absorption (< 30% absorbed in
vivo), (ii) moderate absorption (30–70% absorbed in vivo), and (iii)
excellent oral absorption (> 70% in vivo absorption), the in vivo ab-
sorption ability was correctly predicted for> 80% of the about 30
drugs tested. Further, compounds that were not correctly classiﬁed
were found in the neighbouring class and none of the compounds were
totally mispredicted (Naderkhani et al., 2015). Overall, based on the
permeability values from the tested drugs, the PVPA seems to model the
in vivo absorption better than molecular descriptors and equally well as
the Caco-2 model and the PAMPA-DS model (Flaten et al., 2006b).
3.2.2. Variants of PVPA
The original PVPA has the potential to serve as a general model
mimicking several biological absorption barriers (Naderkhani et al.,
2014a). Nevertheless, by changing the lipid composition of the PVPA,
speciﬁc barriers might be better mimicked. For instance, the biomi-
metic PVPA with a lipid composition more closely approaching that of
the intestinal barrier was introduced to improve passive intestinal
permeability assessment (Naderkhani et al., 2014b). This biomimetic
PVPA barrier consists of 26.5% phosphatidylcholine, 26.5% phospha-
tidylethanolamine, 7% phosphatidylserine, 7% phosphatidylinositol
and 33% cholesterol which provides the barrier with a negative surface
charge thereby better mimicking the lipid composition found in in-
testinal epithelia (Naderkhani et al., 2014b). For positively charged
compounds, an increased permeability was observed with the nega-
tively charged biomimetic barriers. Overall, the degree of correct
Fig. 1. Schematic overview of diﬀerent types of intestinal
drug transport including passive transcellular diﬀusion
(A), passive paracellular diﬀusion (B), active inﬂux
transport (C), active eﬄux transport (D) and transcytosis
(E). Blue and purple boxes represent uptake and eﬄux
transporters, respectively. (For interpretation of the re-
ferences to colour in this ﬁgure legend, the reader is re-
ferred to the web version of this article.)
Fig. 2. Schematic illustration of PAMPA which is typically applied in a 96-well plate. Reprinted from website of Pion Inc. with permission (Pion Inc., 2018).
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classiﬁcation according to the in vivo absorption was comparable with
the original PVPA (Naderkhani et al., 2014b). Since the biomimetic
PVPA model also showed improved storage stability by maintaining its
integrity in the frozen state for a period of 6months compared to
2 weeks for the original PVPA, the biomimetic variant of the PVPA
model might be considered as a step forward in permeability screening.
In addition to this biomimetic PVPA, the mucus-PVPA has recently
been introduced as another variant of the PVPA (Falavigna et al., 2018).
The mucus layer, covering all mucosal surfaces in the human body, is
the ﬁrst barrier encountered by drugs before absorption through epi-
thelial tissues, implying that the mucus layer could aﬀect drug ab-
sorption. It has been suggested that two major mechanisms might in-
ﬂuence the ability of compounds to diﬀuse through the mucus layer: i)
the interaction ﬁltering where the overall hydrophilicity of the mucin
gel mostly hampers the diﬀusivity of lipophilic compounds, whereas
hydrophilic compounds tend to penetrate more easily through this
hydrophilic mucus layer, and ii) the size ﬁltering properties of the
mucin mesh preventing diﬀusion according to the size of the diﬀusing
compound or formulation (Boegh and Nielsen, 2015). The impact of a
mucus layer on intestinal drug absorption has mainly been investigated
using cell-based models. For instance, co-cultures of mucus producing
HT-29 cells and Caco-2 cells have been developed (Lechanteur et al.,
2017) or an additional artiﬁcial mucus layer has been applied on top of
Caco-2 cells (Wuyts et al., 2015a). Since the integrity of the mucus
barrier cannot be assured using these cell-based systems, there is a need
to implement a ﬁxed mucus layer to directly investigate the impact of
mucus on (oral) drug delivery. To meet these shortcomings, the novel
mucus-PVPA was developed which contains the same liposome com-
position as the original PVPA barriers supplemented with an additional
layer of mucus on top of the PVPA-barrier (Falavigna et al., 2018). The
mucus was prepared using unpuriﬁed mucin from porcine stomach type
III in phosphate buﬀer pH 7.4. The reason for choosing this type of
mucin was that the molecular weight, structure and mesh size of pig
mucins resemble what is found in human mucins. This modiﬁed model
has been proven to be stable in the presence of mucus with mucin
concentrations from 10 to 40mg/mL and demonstrated the ability to
discriminate between compounds with diﬀerent chemical structures
and properties. More speciﬁcally, a decrease in drug permeability was
found in the presence of mucus on top of the PVPA barriers. ToTa
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Fig. 3. Schematic illustration of the phospholipid vesicle-based permeation
assay which could be used in Transwell inserts (0.33 cm2) and Millicell well
plates (0.6 cm2). The ﬁlter (cellulose ester) support is shown in pink while the
liposomes of two diﬀerent size distributions and lamellarity are shown in blue;
the liposomes can be found both within the pores as well as on top of the ﬁlter
support. Reprinted from PhD thesis of Flaten with permission (Flaten, 2007).
(For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
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overcome this barrier, drug delivery systems have been designed with
mucoadhesive (chitosan-coated) and/or mucus penetrating (PEGylated)
properties (Naderkhani et al., 2014a; Netsomboon and Bernkop-
Schnürch, 2016). The mucus-PVPA was able to distinguish between the
diﬀerent liposomal formulations, making it a reliable tool in the de-
velopment and optimization of formulations intended for transmucosal
delivery (Falavigna et al., 2018).
3.3. Permeapad®
Permeapad®, which has been developed at the University of
Southern Denmark in 2015, is also a fully artiﬁcial phospholipid-based
biomimetic membrane with a layered structure (di Cagno et al., 2015).
In contrast to PAMPA and PVPA, Permeapad® is composed of phos-
pholipids (soy bean phosphatidylcholine S-100) deposited between two
support sheets (di Cagno et al., 2015). According to the general model
of phospholipid hydration, the lipid crystals are assumed to swell in
contact with water generating within minutes a tightly packed layer of
spheroids consisting of stacks of bilayers with intercalating water
layers, which mimic the cell membrane. As the phospholipids ﬁll the
space between the support layers, the vesicles will remain in close
proximity to their neighbor vesicles and thereby mimic tissue mor-
phology. Furthermore, the support layers protect the lipid layer from
erosion and leakage of lipids into the aqueous environment. For a set of
compounds, Di Cagno and co-workers observed a good linear correla-
tion between permeability coeﬃcients obtained with Permeapad® on
the one hand and the Caco-2 cell assay or PAMPA from literature on the
other hand (di Cagno et al., 2015).
Being available in several ready-to-use formats, as illustrated in
Fig. 4, Permeapad® can potentially serve for several permeability ap-
plications: while high-throughput permeability screening of NCEs
(Permeapad® Plate; Fig. 4(D)) is generally performed using a 96-well
plate, disks of Permeapad® mounted in side-by-side diﬀusion cells or
Franz diﬀusion cells (Fig. 4(B)) are mainly applied for rank ordering
drug formulations. For example, Volkova and co-workers used Per-
meapad® to determine the permeability of a set of novel 1,2,4-thia-
diazole derivatives to evaluate the predictive capacity of in silicomodels
(Volkova et al., 2017). Furthermore, Permeapad® is also available in the
form of inserts for 6-well plates (Fig. 4(C)).
3.4. Artiﬁcial membrane based systems
Dialysis experiments, using a cellulose membrane with a molecular
cutoﬀ weight of 12–14 kDa, are regularly performed to estimate the
bioaccessible fraction since these membranes are impermeable for mi-
cellar and other colloidal structures. These artiﬁcial membranes can
also be used for permeation experiments, which will be exempliﬁed in
this section by the AMI-system. In 2017, the AMI-system has been in-
troduced by the KU Leuven as a new cell-free permeation tool which, in
contrast to the previously described cell-free permeation systems, only
contains an artiﬁcial membrane without any (phospho)lipids to in-
vestigate the passive intestinal permeability of poorly water soluble
drugs (Berben et al., 2018a). To this end, a regenerated cellulose
membrane (molecular weight cutoﬀ 2 kDa) is mounted between two
plastic rings, as depicted in Fig. 5. Using this AMI-system, the perme-
ability of 14 diﬀerent poorly water-soluble drugs dissolved in both
fasted state simulated and human intestinal ﬂuids (FaSSIF/FaHIF), was
assessed. For this set of compounds, covering a broad range of physi-
cochemical properties, a good correlation (Pearson correlation coeﬃ-
cient r of 0.95) was observed with the commonly used Caco-2 cell
model when FaHIF was used as donor solvent system. Additionally, the
apparent permeability coeﬃcients obtained when using FaSSIF and
FaHIF correlated nicely using the AMI-system, indicating the usefulness
of FaSSIF as surrogate medium for FaHIF (Berben et al., 2018a).
Overall, due to the limited preparation steps of this recently introduced
permeation tool, the AMI-system may be considered as a high-
throughput and cost-eﬀective tool for passive permeability proﬁling of
poorly water-soluble drugs.
As previously mentioned (cfr. 3.2.2.), the intestinal mucus layer,
which is often ignored in permeability proﬁling, is of considerable in-
terest since this layer may drastically aﬀect the intestinal absorption of
lipophilic drugs and may function as a drug depot for (mucoadhesive)
nanoparticles (Behrens et al., 2001; Netsomboon and Bernkop-
Schnürch, 2016). To investigate the impact of a mucus layer, Stappaerts
et al. recently described a slightly modiﬁed version of the AMI-system
where a mucus layer was added between a dialysis membrane (pore size
2 kDa) and a ﬁlter membrane (pore size 1 μm), as illustrated in Fig. 6
(Stappaerts et al., 2017). The thickness of the mucus layer (± 120 μm)
and the mucin concentration (50mg/mL) closely approach reported in
vivo values (Ensign et al., 2012). Since the relatively large pore size of
the ﬁlter membrane on top of the mucus layer successfully retains the
mucus and allows free permeation of drugs, this model enables to study
the interaction of drugs with mucus and its implications on intestinal
drug permeation. For instance, it was demonstrated that the transport
of the lipophilic compound heptylparaben was strongly impeded by the
implementation of a mucus layer in the AMI-system. However, this
diﬀusion limiting eﬀect of the mucus layer was neutralized by (i) the
addition of relatively low concentrations of hydroxypropyl-β-
Fig. 4. Schematic representation of the avail-
able formats of the Permeapad® barrier. A. Bulk
sheet of Permeapad®, B. Disk of Permeapad®
compatible with side-by-side diﬀusion cells and
Franz diﬀusion cells, C. Insert with Permeapad®
for 6-well plates (surface area of 3.8 cm2), D.
Permeapad® plate, a 96-well plate with a surface
area of 0.13 cm2 for high throughput permea-
tion screening with: D1 lid, D2 middle plate with
Permeapad® as barrier and D3 bottom well-
plate.
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cyclodextrin (HP-β-CD) to the phosphate buﬀer in the donor compart-
ment or (ii) by the use of biorelevant media (FaSSIF) as donor solvent
system. These results indicate that the implementation of a mucus layer
in the AMI-system enables to mechanistically evaluate the impact of
mucus on drug permeation.
4. The usefulness of cell-free permeation tools in oral drug
delivery studies
Since a sizable fraction of NCEs have a low solubility in intestinal
ﬂuids that may limit their oral absorption, solubility enhancers are
regularly employed in formulation development; in addition, food may
aﬀect as well the absorption of these low solubility NCEs (Loftsson and
Brewster, 2010). In view of the fact that (i) information on the impact
of these pharmaceutical excipients and/or food components on drug
permeability is scarce and (ii) they may compromise the barrier in-
tegrity of several cell-based permeation tools (e.g. Caco-2 cells), there is
an increased interest to implement cell-free permeation systems in
formulation testing. A number of mechanisms may contribute to the
incompatibility of Caco-2 cells towards diﬀerent intestinal conditions.
(i) In contrast to the in vivo situation, Caco-2 cells are not covered by a
mucus layer which protects the enterocytes in the human intestinal
tract from toxic eﬀects of endo- and exogenous substances. (ii) Caco-2
cells are exposed to the donor medium during the entire transport ex-
periment; in vivo, transit along the intestinal tract results in a reduced
exposure time to the intestinal epithelium. In speciﬁc cases, an eﬀect of
excipients on monolayer integrity is targeted. For example, it is known
that permeation enhancers, which aim to increase the intestinal ab-
sorption of proteins and peptides, rely on the temporarily disruption of
the intestinal lining by opening the tight junctions to allow oral ab-
sorption of the peptide or protein via the paracellular route (McCartney
et al., 2016). Since cell-free permeation systems are limited to the
prediction of passive transcellular diﬀusion, other permeation systems
are required to investigate the eﬀect of permeation enhancers.
In this section, an overview of the robustness of these cell-free
permeation models towards the harsh conditions from the intestinal
environment is provided and how these systems might be used for
evaluating the performance of oral drug delivery systems within the
ﬁeld of drug discovery and development.
4.1. Robustness
Independent of the nature of the barrier (cellular or non-cellular),
experimental evidence of barrier integrity is essential to establish a
reliable permeation screening protocol. Traditionally, non-invasive
techniques are preferred to check the barrier integrity continuously
during a permeation experiment. Such techniques are mainly based on
the measurement of the transepithelial electrical resistance (TEER).
Although originally designed for conﬂuently growing cells cultured on
porous membranes, the same approach is frequently used for cell-free
barriers (Fischer et al., 2011, 2012). Another, more direct assay in
terms of functional integrity is to measure the permeability of hydro-
philic, low permeability model compounds, such as calcein, carboxy-
ﬂuorescein, Lucifer Yellow, Trypan Blue, mannitol or dextran. For
practical reasons, ﬂuorescence-labeled substrates are preferred; de-
pending on the interference between marker and drug, they may be
included in the same run as the drug of interest. Finally for biomimetic
barriers, a leaching of barrier-constituents such as phosphatidylcholine
into the donor compartment may serve as an indicator for partial
breakdown of the barrier (Flaten et al., 2008). Hence, within this sec-
tion, the functional stability of the lipid-based cell-free permeation as-
says towards diﬀerent pH values, pharmaceutical excipients and bio-
mimetic media is extensively described and summarized in Table 2.
Given the fact that the AMI-system only contains a regenerated cellu-
lose membrane, this permeation tool is not discussed since it is sup-
posed that the AMI-system easily resists bile salts, enzymes, and (di-
gesting) products; indeed, permeation experiments applying FaSSIF and
FaHIF as donor medium did not result in any stability issues (Berben
et al., 2018a).
4.1.1. pH
Riethorst et al. observed that, in a medium-scale clinical trial with
20 healthy volunteers, the pH of the duodenal ﬂuids collected in the
fasted state was highly variable, ranging from 3.4 to 8.3 (Riethorst
Fig. 5. Schematic representation of the AMI-system; green surface (4.91 cm2) represents the regenerated cellulose membrane as barrier (Berben et al., 2018a). (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 6. Schematic representation of the AMI-system consisting of a mucus layer (brown droplets) on a dialysis membrane (green surface) which is retained by an
additional membrane ﬁlter (grey surface) allowing to investigate the inﬂuence of a mucus layer on the intestinal drug permeation, reprinted with permission
(Stappaerts et al., 2017). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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et al., 2016). Another research group reported that the pH at the surface
of the epithelial cells is signiﬁcantly lower (pH 5.5) than the pH of the
bulk solution due to the presence of the mucus layer on top of the cells
(Shiau et al., 1985). In order to reliably evaluate the permeation po-
tential of drugs and/or the eﬀect of pH on drug permeation, it is es-
sential that the cell-free permeation systems are robust over this wide
pH range. While cell monolayer assays tolerate only a narrow pH range
(monolayer integrity tends to be compromised at pH values lower than
6.5), PAMPA and PVPA barriers have been proven to be stable in a pH
range from 2 to 8. These systems are thus suitable as permeability
model to evaluate segmental intestinal absorption as well as absorption
from sites with a broad pH range (Bermejo et al., 2004; Flaten et al.,
2006a; Wohnsland and Faller, 2001; Zhu et al., 2002). Using the PVPA,
acidic and basic drugs also showed pH-dependent permeability ac-
cording to the pH partition theory (Flaten et al., 2006a; Naderkhani
et al., 2014b). For example, permeation of acids is regularly under-
estimated when measuring the permeation in vitro at pH 7.4 only.
Likewise, the Permeapad® barrier demonstrated to withstand the phy-
siologically relevant pH range since the permeation of the non-ionisable
compound hydrocortisone was unaﬀected at diﬀerent pH values be-
tween 1 and 9 (di Cagno et al., 2015) and this barrier showed pH-de-
pendent permeability for dissociating APIs (see also Section 5.3.).
4.1.2. Pharmaceutical excipients
Permeability is considered as a key parameter to evaluate the de-
velopability of NCEs. Hence, permeability screening is an integral part
of drug discovery and/or early stages of drug development. During drug
discovery, spiked dimethyl sulfoxide (DMSO) stock solutions are typi-
cally applied in high throughput screening, including permeation
screening of NCEs. In early stages of drug development, high doses are
Table 2
Robustness of PAMPA, PVPA and Permeapad® in the presence of co-solvents, surfactants, other excipients and biomimetic media.
Permeation assay Integrity test method Time (h) Additives (co-solvents, surfactants,
biomimetic media)
Concentration Compatibility Ref.
PAMPA (2% DOPC in n-
dodecane)
Permeation of Lucifer yellow 16 Ethanol
Tween 80
Brij 35
0.1–5%
0.1–5%
0.1–5%
✔
✔
✔
(Liu et al., 2003)
Cremophor EL 0.5% Not compatible
PAMPA biomimetic Permeation of trypan blue 2 Ethanol
DMSO
PEG 400
Up to 30%
Up to 30%
Up to 30%
✔
✔
✔
(Sugano et al., 2001)
Double-sink™ PAMPA Permeation of Lucifer Yellow 20 FaSSIF-v2e
FeSSIF-v2e
–
–
✔
✔
(Markopoulos et al.,
2013)
Pre-coated PAMPA Permeation of 8 high and low
permeability compounds
4–5 Methanol 20% ✔ (Chen et al., 2008)
PVPAoriginal Permeation of calcein,
electrical resistance,
phospholipid release
5 Ethanol
DMSO
20mg/mL
20mg/mL
✔
✔
(Flaten et al., 2008)
PEG 400 40mg/mL ✔
Tween 80
Brij 35
Cremophor EL
0.5–1mg/mL
0.5–1mg/mL
1mg/mL
Not compatible
Not compatible
Not compatible
Span 20 5mg/mL ✔
4 FaSSIFe – ✔ (Fischer et al., 2012)
Permeation of calcein,
electrical resistance
4.5 Vinylpyrrolidone/vinylacetate – ✔ (Kanzer et al., 2010)
5 Gelucire 44/14a
Cremophor RHb
Solutol HS 15c
< 1mg/mL
<1mg/mL
<1mg/mL
✔
Not compatible
Not compatible
(Fischer et al., 2011)
Triton-X 0.5mg/mL Not compatible
Poloxamer 188 10mg/mL ✔
PVPAbiomimetic Permeation of calcein,
electrical resistance
5 Ethanol
DMSO
40mg/mL
40mg/mL
✔
✔
(Naderkhani et al.,
2014b)
PEG 400 60mg/mL ✔
Tween 80
Brij 35
0.5–1mg/mL
0.5–1mg/mL
(✔)d
(✔)d
Cremophor EL 5–40mg/mL (✔)d
Span 20 20mg/mL ✔
Poloxamer 188 60mg/mL ✔
Permeation of calcein, electrical
resistance, phospholipid release
12 FaSSIF-v2e –
–
✔
✔
(Naderkhani et al.,
2015)FeSSIF-v2e
Permeapad® Permeation of calcein 5 Ethanol 40% ✔ (Bibi et al., 2015)
DMSO 10% ✔
Tween 60 4% ✔
Tween 80
Cremophor EL
Sodium dodecyl sulfate
5%
5%
5%
✔
✔
✔
Triton-X 1% ✔
FaSSIFe
FeSSIFe
FaSSIF-v2e
FeSSIF-v2e
–
–
–
–
✔
✔
✔
✔
AMI-system Permeation of 14 low solubility
compounds
FaSSIFe
FaHIF
–
–
✔
✔
(Berben et al., 2018a)
a Polyoxyl 32 glycerides.
b Polyoxyl 40 hydrogenated castor oil.
c Polyoxyl 15 hydroxystearate.
d Calcein permeability increased signiﬁcantly, electrical resistance remained within the limits set which indicate maintenance of barrier integrity.
e Commercially available from biorelevant.com.
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often required to assess the therapeutic safety margin, and the for-
mulations used are relatively simple (e.g. co-solvent systems based on
polyethylene glycol (PEG) 400). Since most of the cell-free permeation
assays discussed so far contain lipid components, co-solvents represent
a challenge for permeation barrier integrity due to potential extraction
of the barrier's lipidic constituents (Flaten et al., 2008). Robustness of
the permeability barriers against the co-solvents used should thus be
established to obtain valid permeation data in the presence of co-sol-
vents. During later development phases, the selection of the best for-
mulation strategy for a drug candidate is in focus. Especially poorly
soluble drugs require advanced formulations (i.e. absorption enabling
formulations), often containing solubilizing excipients, to render them
bioavailable. In order to rank the performance of the formulations,
permeation tools are increasingly employed in recent years as they may
allow to rank various pharmaceutical formulation concepts according
to their ability to enhance bioavailability (Buckley et al., 2013). Gen-
erally, the ranking of diﬀerent formulations according to their in vitro
(permeation) performance is desirable to minimize animal usage.
However, it should be noted that solubilizing excipients such as sur-
factants or lipids represent a challenge for permeation barrier integrity
due to potential dissolution and/or emulsiﬁcation of the barrier's lipidic
constituents. Additionally, cyclodextrins represent a challenge for ar-
tiﬁcial barriers containing cholesterol, which can be employed as sta-
bilizing barrier component, as β-cyclodextrins are able to chelate cho-
lesterol (Zidovetzki and Levitan, 2007). Robustness of the employed
permeability barriers against co-solvents and solubilizing formulation
additives should thus be thoroughly established.
The robustness of PAMPA towards pharmaceutical excipients could
be highly diﬀerent across the multiple variants of PAMPA due to dif-
ferences in composition of the barrier. By determining the permeability
of Lucifer Yellow in the presence and absence of additives, Liu et al.
reported that a PAMPA barrier consisting of a hydrophobic ﬁlter im-
pregnated with 2% dioleoylphosphatidylcholine in n-dodecane main-
tained its integrity in the presence of up to 5% ethanol and 5% of the
non-ionic surfactants polysorbate 80 (Tween 80) and polyoxyl 23
laurylether (Brij 35), respectively. On the other hand, PAMPA barrier
integrity was compromised in the presence of 0.5% ethoxylated castor
oil (Cremophor EL) (Liu et al., 2003). Sugano et al. investigated the
eﬀect of co-solvents on a biomimetic PAMPA model to determine the
optimal conditions for the prediction of oral drug absorption (Sugano
et al., 2001). Here, biomimetic refers to the (phospho)lipid solution
containing 0.8% phosphatidylcholine, 0.8% phosphatidylethanolamine,
0.2% phosphatidylserine, 0.2% phosphatidylinositol and 1% choles-
terol (total lipid content 3%) in 1.7-octadiene used for ﬁlter impreg-
nation, which should reﬂect the (phospho)lipid composition found in
the intestinal brush border (Proulx, 1991). By measuring the appear-
ance of the non-permeable marker Trypan Blue in the acceptor com-
partment, the maintenance of integrity of the biomimetic PAMPA bar-
rier was demonstrated in the presence of up to 30% ethanol, DMSO or
PEG 400 (Sugano et al., 2001). It is well established that cholesterol has
a stabilizing eﬀect on phospholipid bilayers and vesicles as cholesterol
is known to increase the rigidity of the bilayer (Brandl, 2001). Thus, it
may be hypothesized that the comparatively high cholesterol content
(1/3 of lipids) may aid PAMPA barrier stability in the presence of co-
solvents at this relatively high concentration.
To the best of our knowledge, no speciﬁc stability data in the pre-
sence of co-solvents or excipients are available in literature for PAMPA-
DS employing a surfactant to create sink conditions. However, the eﬀect
of excipients on the permeability of eight sparingly soluble compounds
was studied using PAMPA-DS. The excipients studied included 2-hy-
droxypropyl-β-cyclodextrin, sodium taurocholate and the co-solvents 1-
methyl-2-pyrrolidone, propylene glycol, and PEG 400. Stability issues,
based on drug permeation and membrane retention, were not addressed
with the exception of sodium taurocholate which appeared to com-
promise PAMPA-DS barrier integrity at a concentration of 15mM
(Bendels et al., 2006). Using the PAMPA model, Avdeef et al. assessed
the impact of single excipients including solubilizing agents, co-solvents
and organic compounds on the absorption potential of test compounds
and concluded that the presence of an excipient mainly decreased
permeability, but most often not by the same extent as solubility was
increased (Avdeef et al., 2008).
With a markedly reduced organic solvent content as compared to
the original PAMPA models, the barrier of the Corning® Gentest™ pre-
coated PAMPA plate system consists of a PVDF ﬁlter and phospholipid-
hexadecane-phospholipid tri-layers dissolved in the volatile solvent
hexane (Chen et al., 2008). By determining the permeation of 8 com-
pounds, including high and low permeability compounds, in the pre-
sence of 10% methanol, the barrier integrity of the pre-coated PAMPA
model was maintained as only slight increases in permeability for
highly permeable compounds and no increase in permeability for low
permeability compounds were observed. In the presence of 20% me-
thanol, a noticeable increase in permeability for low permeable com-
pounds was observed implying that the integrity of the artiﬁcial barrier
was impaired. Moreover, barrier integrity was completely lost in the
presence of 30% methanol as permeability values were dramatically
increased (Chen et al., 2008). According to technical information from
the manufacturer, the pre-coated PAMPA model is also compatible with
5% DMSO, 10% acetonitrile and other organic solvents.
Furthermore, the pre-coated PAMPA plate system was used to
conduct a head-to-head comparison of diﬀerent solubility-enabling
formulations of the poorly soluble anticancer drug etoposide (Beig
et al., 2015). The etoposide formulations tested were solutions of hy-
droxypropyl-β-cyclodextrin, sodium dodecyl sulfate (SDS) and PEG 400
as well as a co-povidone based amorphous solid dispersion (ASD). Beig
et al. showed that formulations reducing the free fraction of etoposide
lead to a concomitant decrease in etoposide apparent permeability. In a
later study investigating the solubility-permeability interplay of eto-
poside, Beig et al. used the same PAMPA model to investigate the
permeability for etoposide formulated as D-α-tocopheryl polyethylene
glycol 1000 succinate (TPGS) solution compared to a polymer-based
etoposide ASD. Again, it was demonstrated that TPGS-based formula-
tions resulted into a concomitant decrease in in vitro etoposide perme-
ability (Beig et al., 2017b). The same PAMPA model was used to
evaluate the performance of rifaximin ASDs whereby higher con-
centrations were translated into a higher ﬂux due to lack of the solu-
bility-permeability interplay (Beig et al., 2017a). It should be men-
tioned that, in none of these studies, barrier compatibility with the
tested excipients was explicitly tested. However, the eﬀects of surfac-
tants on the integrity of artiﬁcial barriers should be carefully considered
to obtain unbiased results as observed eﬀects on permeability in the
presence of these compounds may result not only from (micellar)
complexation (solubility-permeability interplay), but also from poten-
tial changes of the membrane properties. According to technical in-
formation by the manufacturer, surfactants may potentially disturb
integrity of the pre-coated hexane-based PAMPA membrane. This is in
agreement with results from Könczöl et al. and Müller et al. who argued
that hexane-based PAMPA barriers may be more susceptible for barrier
instability than n-dodecane-based PAMPA barriers in harsh environ-
ments (Könczöl et al., 2013; Müller et al., 2015), which could possibly
be explained by the more volatile properties of hexane.
In the case of the original PVPA, it was found that the integrity of
this barrier did not seem to be inﬂuenced by 40% of PEG 400, 20% of
ethanol or 20% DMSO (Flaten et al., 2007, 2008). Also Poloxamer 188
did not aﬀect barrier integrity in all the tested concentrations (up to
50%) (Fischer et al., 2011). Conversely, Brij 35, Tween 80 and Cre-
mophor EL were found to be incompatible with the model at all con-
centrations as the barriers became leaky (Flaten et al., 2008). Fur-
thermore, the original PVPA model has been used to study diﬀerent
solubility-enabling formulations. Kanzer et al. tested three prototypes of
melt extrudates containing the poorly water-soluble drugs HIV-PI 1 and
HIV-PI 2 (Kanzer et al., 2010). All formulations contained a vi-
nylpyrrolidone/vinylacetate copolymer matrix supplemented with
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diﬀerent surfactants (sorbitan monolaurate, Cremophor EL and propy-
lene glycol laurate). The integrity of the barriers were investigated in
the presence of the vinylpyrrolidone/vinylacetate copolymer matrix
alone, placebo versions of the three formulations as well as the drug-
containing formulations (Kanzer et al., 2010). Except for the Cremo-
phor EL containing solid dispersion, no inﬂuence on the integrity of the
PVPA barriers was observed according to calcein permeability and
electrical resistance measurements for up to 3 h. In other studies, dif-
ferent drug containing liposome formulations composed of phosphati-
dylcholine or a combination of phosphatidylcholine and phosphati-
dylglycerol have been investigated using the PVPA (Falavigna et al.,
2018; Naderkhani et al., 2014a). These formulations were further PE-
Gylated or coated with Carbopol or chitosan. When using electrical
resistance measurements, none of the tested formulations appeared to
impair the integrity of the barrier. In comparison with the original
PVPA, the biomimetic PVPA demonstrated to be more robust
(Naderkhani et al., 2014b), since its barrier integrity was not disrupted
by any of the tested surfactants and co-solvents, not even in the pre-
sence of 0.5mg/mL Triton X (originally included as a positive control).
Given the fact that the biomimetic membrane Permeapad® consists
of one or more layers of (phospho-)lipids sandwiched between two
polymeric supports, the (phospho)lipid layer is separated from the
surrounding media. Plausibly, this may aid to maintain the barrier in-
tegrity in harsh environments. As such, Bibi et al. have investigated the
integrity of the Permeapad® barrier in the presence of various (co)-
solvents and surfactants by determining the permeability for calcein
over the Permeapad® barrier using both a Franz and side-by-side dif-
fusion cell set-up for a period of 5 h (Bibi et al., 2015). Results de-
monstrated that Permeapad® was compatible with at least 10% DMSO
and 40% ethanol. In addition, integrity of Permeapad® was investigated
for several surfactants including Cremophor EL (0.1–5%), polysorbate
60 (Tween 60, 2 and 4%), Tween 80 (0.05–5%), SDS (0.1–5%) and
Triton-X (0.5 and 1%). Using Franz diﬀusion cells, the Permeapad®
barrier appeared to be compatible with all tested surfactants except for
Cremophor EL (slight increase in calcein permeability), which also
compromised the integrity of the original PVPA (Flaten et al., 2008)
and PAMPA barrier (Liu et al., 2003). To investigate whether the in-
creased calcein permeability in the presence of Cremophor EL was
caused by barrier instability or other eﬀects, explorative barrier func-
tionality/stability studies were carried out using another set up (side-
by-side diﬀusion cells instead of Franz diﬀusion cells). To this end, a
calcein permeation experiment in the presence of Cremophor EL was
performed for 5 h, followed by washing the Permeapad® barrier with
PBS and a new calcein permeability experiment in the absence of the
surfactant showed unchanged permeation properties (Bibi et al., 2015).
4.1.3. Biomimetic media
When considering oral drug administration, the inﬂuence of gas-
trointestinal colloidal structures on the absorption of especially poorly
soluble drug compounds is well recognized. In recent years, biomimetic
media, i.e. media mimicking the composition of human intestinal ﬂuid
in diﬀerent prandial states containing bile salts, phospholipids and/or
fatty acids, have become increasingly popular in dissolution testing
(Galia et al., 1998; Mann et al., 2017; Wagner et al., 2012) and sub-
sequently also in permeation testing (Ingels et al., 2004; Wuyts et al.,
2015b, 2015a). Bile salts, fatty acids and other compounds present in
the gastrointestinal environment are known to be detrimental for Caco-
2 cell monolayers and may potentially compromise the integrity of
permeation barriers containing lipid constituents as these surfactants
may lead to emulsiﬁcation. Also (pancreatic) enzymes able to cleave
(phospho)lipids into digestion products (fatty acids, mono-/di-glycer-
ides, lyso-phospholipids) are considered as an additional threat to the
permeability barriers. Obviously, prior to prediction of oral drug ab-
sorption, compatibility of the permeability barrier with intestinal
structures including bile salts, (phospho)lipids, (pancreatic) enzymes,
and digestion products should be carefully investigated.
With regard to compatibility of PAMPA with (simulated) intestinal
ﬂuids, Markopoulos et al. validated PAMPA-DS barrier integrity by
determining the permeability of Lucifer Yellow in the presence and
absence of simulated intestinal ﬂuids (Markopoulos et al., 2013). The
authors observed that the PAMPA-DS barrier retained its integrity for at
least 20 h when fasted or fed state simulated intestinal ﬂuid version 2
(FaSSIF-v2 or FeSSIF-v2, respectively) were used as donor medium.
Furthermore, PAMPA-DS barrier integrity was maintained for up to 8 h
in the presence of aspirates from the upper small intestine collected
from healthy volunteers at various time points after the administration
of a heterogenous danazol and olive oil containing meal. However,
PAMPA-DS barrier was stable for only 40min in the presence of the
micellar phase of aspirates (supernatant of ultracentrifuged aspirate).
While the bile salt content in this supernatant was in the same order of
magnitude as in the aspirates, the content of lipidic constituents was
reduced considerably. It was hypothesized that emulsiﬁcation of
PAMPA barrier constituents by bile salts was prevented by encapsula-
tion of bile salts in coarse lipid particles (Markopoulos et al., 2013).
Analogous ﬁndings were obtained in a Caco-2 experiment utilizing
FeSSIF as donor medium (Patel et al., 2006). Here it was found that, by
reducing the bile to lecithin ratio, compatibility of the Caco-2 per-
meation assay with a modiﬁed FeSSIF medium could be achieved.
Also the original PVPA was demonstrated to be compatible with
FaSSIF while the integrity towards the more challenging FeSSIF has
never been tested (Fischer et al., 2012). However, the biomimetic PVPA
barrier maintained its integrity in the presence of both FaSSIF-v2 and
FeSSIF-v2 implying that the intestinal environment could be more
closely mimicked during permeability estimations compared to the
original PVPA (Naderkhani et al., 2015). The compatibility was de-
monstrated using permeability for the hydrophilic marker calcein as
well as electrical resistance across the barriers.
The Permeapad® barrier demonstrated to be compatible for 5 h with
FaSSIF, FaSSIF-v2 and FeSSIF-v2; however, calcein permeability was
signiﬁcantly increased in the presence of FeSSIF(-v1), which could
possibly be attributed to an increased osmolality of FeSSIF in compar-
ison to the other simulated intestinal media. Nevertheless, after re-
moving FeSSIF, permeability of calcein (now dissolved in PBS), was no
longer signiﬁcantly increased and thus compatibility established (Bibi
et al., 2015). Moreover, Permeapad® is the only artiﬁcial barrier system
that has been used under lipolytic conditions for in vivo relevant for-
mulation evaluation so far. More speciﬁcally, the performance of self-
nanoemulsifying drug delivery systems (SNEDSS) of cinnarizine was
investigated using the Permeapad® barrier (Bibi et al., 2017). Vali-
dating studies using calcein showed that the Permeapad® barrier
maintained its integrity in the presence of lipolysis medium containing
a pancreatic extract with a lipase activity of 600 USP/mL over a period
of 4 h. Additionally, the Permeapad® barrier was found compatible with
self-emulsifying drug delivery systems consisting of oleic acid, sesame
oil, ethanol, Cremophor EL and Brij 97. Barrier integrity was even
maintained in the presence of both lipolysis medium and SNEDDSs
allowing to reliably investigate lipolysis and permeation in parallel
(Bibi et al., 2017).
Overall, it can be concluded that the holding time for the diﬀerent
biomimetic barriers in the presence of excipients and/or colloidal
structures may vary widely, implying that the time window to perform
the permeation experiments should be selected properly.
4.2. Importance of stirring and sink conditions
The unstirred water layer (UWL) is generally considered as an ad-
ditional permeation barrier in in vitro assays, mainly hampering the
permeation of lipophilic compounds. While the UWL is relatively small
(30–100 μm) in the human intestinal tract due to relatively high mo-
tility, values of> 2000 μm are frequently reported for in vitro assays
(Lennernäs, 1998). For example, the calculated thickness of the UWL
adjacent to Caco-2 cell monolayers amounted to 2000 μm while values
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up to 3800 μm have been estimated in PAMPA assays (Hidalgo et al.,
1991; Nielsen and Avdeef, 2004). However, several research groups
have demonstrated that by increasing the stirring speed of the per-
meation set-up, the thickness of the UWL could be reduced to the in vivo
range (Avdeef et al., 2004; Hidalgo et al., 1991). Hydrodynamics also
appeared to be important when studying permeation using the AMI-
system: the apparent permeability coeﬃcient for 11 out of 14 com-
pounds was clearly higher when applying stirring (300 rpm versus no
agitation); no further enhancement was observed upon increase of
agitation to 700 rpm (Berben et al., 2018a). Conversely, PVPA diﬀers
from other permeability models in the sense that mechanical agitation
did not result into increased permeability, not even for highly lipophilic
drugs such as testosterone. This might be explained by the structure of
the PVPA barriers which consist of liposome ﬁlled ﬁlter pores together
with a layer of liposomes on top of the ﬁlter (Flaten et al., 2006a);
inside the liposomes, there are aqueous compartments that will not be
aﬀected by the stirring of the system. As a result, even though a wider
range of permeability values could be observed for drugs with human
fraction absorbed above 90%, permeability data obtained without the
use of agitation already correlate well with the fraction absorbed in
humans after oral administration, also for the highly lipophilic com-
pounds (Flaten et al., 2006b; Naderkhani et al., 2015).
Along with an adequate agitation during (non)-cell-based transport
experiments, sink conditions are often maintained by including a sur-
factant-based solution in the acceptor compartment to avoid back ﬂux
of permeated drug. For instance, TPGS is often added as micelle-
forming agent to entrap the permeated drug. In addition to the use of
surfactants, sink conditions can also be created by applying serum
proteins (e.g. bovine serum albumin (BSA)) or by frequently moving the
permeation barriers to fresh acceptor medium. Moreover, surfactants
and BSA in the receiver compartment are also beneﬁcial to minimize
drug adsorption to the permeation device avoiding loss of drug and a
biased assessment of drug permeation.
All currently employed geometries have a relatively small permea-
tion area in relation to the volume of the donor phase. The physiolo-
gical area-to-volume ratio is estimated to be between 1.9 cm−1 and
2.3 cm−1 (Mudie et al., 2012). In contrast, the area-to-volume ratio of
most permeation setups described in literature is< 0.5 cm−1. Accord-
ingly, only a very minor fraction of the drug permeates within phy-
siological relevant time frames, i.e. steady-state permeability values are
reported by such approaches. Such steady-state permeability values
have found widespread use within predictive pharmacokinetic model-
ling although they do not capture the potential mutual inﬂuence be-
tween dissolution and permeation, as it is expected to occur in vivo,
especially with poorly soluble drugs and enabling formulations. The use
of permeation screens within combined dissolution-/permeation-ap-
proaches and adequate geometries employed for such type of studies
are discussed in more detail in the next chapter.
4.3. Integration of cell-free permeation systems in dissolution testing
Pharmaceutical excipients and/or concomitant food intake may
lead to an increase of intraluminal concentrations of poorly water so-
luble drugs. Over the past two decades, a range of cellular dissolution/
permeation systems have been designed to simultaneously evaluate the
impact of pharmaceutical excipients and/or food components on dis-
solution and permeation behavior of drugs (e.g. dissolution/permeation
system using a Caco-2 cell monolayer) (Kataoka et al., 2003). Due to the
inherent poor robustness of cell monolayers against formulation ex-
cipients and/or food (digestion) products, cell-based systems are lim-
ited in their applicability for formulation evaluation. Since the ro-
bustness of cell-free permeation systems against harsh intestinal
conditions is thoroughly validated and described in literature (cfr. 4.1),
cell-free permeation systems are very useful alternatives to integrate a
permeation compartment into formulation testing (Buckley et al.,
2012).
As such, Lovering and Black already pointed out in their pioneering
work that polydimethylsiloxane dialysis membranes are useful to de-
termine the permeable fraction during a dissolution experiment and
may thus help to predict intestinal absorption for a series of drugs
(Lovering and Black, 1973). An early use of a cell-free permeation
screening includes PVPA for surfactant-based formulations (Fischer
et al., 2011). Furthermore, a modiﬁed version of the original PVPA has
been successfully used in a combined dissolution/permeation system
for testing of solid dosage forms. Permeation data from both fast and
slow releasing tablet formulations showed an excellent correlation with
a similar system using Caco-2 cells as intestinal permeation barrier
(Gantzsch et al., 2014).
Sironi et al. used a pair of side-by-side diﬀusion cells separated by a
hydrophilic cellulose hydrate membrane to predict the gastrointestinal
and absorptive behavior of two commercial fenoﬁbrate formulations by
measuring dissolution and permeation simultaneously for raw fenoﬁ-
brate powder, a nano- and a microparticle formulation (Sironi et al.,
2017b). When using phosphate-buﬀered saline (PBS), the fenoﬁbrate
permeation from the diﬀerent formulations increased according to the
dissolved concentrations measured in the donor compartment: fenoﬁ-
brate powder < microparticles < nanoparticles. The same rank order
was observed when comparing the ﬂux values using biomimetic media
(FaSSIF and FeSSIF) as donor solvent system. However, permeation rate
was unaﬀected when comparing diﬀerent donor media (PBS, FaSSIF or
FeSSIF) implying that micellar solubilization by FaSSIF- or FeSSIF-mi-
celles did not have a signiﬁcant impact on the permeation rate.
Recently, Bibi et al. evaluated the feasibility of combining lipid
digestion (lipolysis) and in vitro permeation using Permeapad® as per-
meation barrier for a lipid based formulation of cinnarizine (Bibi et al.,
2017). Although the focus of this work was on the functional stability of
the barrier during lipid digestion (cfr. 4.1.3), a signiﬁcant change in
drug permeation from SNEDDS was demonstrated when comparing in
vitro permeation from the formulation as such with that obtained
during digestion. These ﬁndings indicate that meaningful in vitro bio-
pharmaceutical evaluation of lipid-based formulations requires a dy-
namic simulation of lipolysis and permeation.
In order to monitor donor drug concentrations during dissolution/
permeation experiments, another technique has been suggested by Fong
et al. and Koplin et al. (Fong et al., 2017; Koplin et al., 2017). As il-
lustrated in Fig. 7A, the suggested microdialysis-dissolution/permea-
tion (M-D/P) system is intended for the biopharmaceutical assessment
of oral drug formulations. The M-D/P system consists of a side-by-side
diﬀusion chamber, a commercial microdialysis probe submersed into
the dissolution chamber for continuous sampling, and the biomimetic
Permeapad® barrier separating the dissolution compartment from the
acceptor compartment. The concentration of molecularly dissolved
drug in the dissolution compartment can be monitored over time using
microdialysis, while the concentration of the permeated drug is fol-
lowed by conventional sampling. In a proof-of-concept study, the ap-
plicability of the M-D/P system for slowly dissolving crystals of hy-
drocortisone solvate (HCS) in buﬀer and FaSSIF was evaluated.
Compared to the traditional direct sampling from the donor compart-
ment using ﬁlters of 0.1–0.45 μm pore size, microdialysis-sampling
exhibited distinct advantages including (i) minimal disturbance of the
interactive dissolution/permeation-process, (ii) discrimination between
“molecularly” dissolved drug (which is considered as the free drug
concentration) and micelle-associated dissolved drug (in the case of
FaSSIF), and (iii) close to real-time monitoring with probe-equilibration
times of 10min or less. The authors concluded that the M-D/P system
allows a comprehensive evaluation of the dynamic interplay of dis-
solution and permeation, which is promising for oral formulation per-
formance ranking and mechanistic studies.
In recent decades, dissolution/permeation models based on non-
biomimetic barriers have been designed, like the TNO model of dy-
namic gastric and intestinal transit and absorption, which is being used
for food and drug studies (Blanquet et al., 2004). Recently, the
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capability of the dialysis membrane-based AMI-system as predictive
tool to explore the ranking performance of diﬀerent absorption-en-
abling formulations was evaluated (Berben et al., 2018b). Prior to
permeation assessment using the AMI-system, a two stage dissolution
test was performed, as depicted in Fig. 7B, for three selected formula-
tions for which in vivo intraluminal and systemic data were available.
The acquired permeation data clearly demonstrated that the AMI-
system enables to correctly predict the eﬀects of (i) formulation pH on
posaconazole dissolution and absorption (Hens et al., 2016), (ii) dilu-
tion on cyclodextrin-based itraconazole absorption (Berben et al.,
2017), and (iii) food intake on fenoﬁbrate absorption (Hens et al.,
2015). Based on these data, simple dissolution testing combined with
this newly developed permeation system appears suitable to be im-
plemented as a time- and cost-eﬀective tool in the early-stage evalua-
tion of absorption-enabling formulations.
When combining dissolution testing with permeation studies,
Buckley et al. suggested to investigate the kinetics of the interrelated
dissolution and permeation processes (Buckley et al., 2013). In such
scenarios, the donor concentration is subjected to continuous changes
and the donor and acceptor proﬁles are dynamically inter-connected.
For instance, slow dissolution of the drug or depletion of the donor
compartment will result in non-steady state conditions. In view of the
importance of balancing these processes in a predictive model, there is
currently limited experimental evidence on the optimal geometry of
such a combined dissolution/permeation setup in order to quantita-
tively predict the in vivo behavior of (enabling) formulations.
A recent study aimed at exploring the capabilities and geometrical
constraints of a conventional side-by-side (Ussing chamber) dissolu-
tion/permeation setup, which was equipped with a biomimetic barrier
(Permeapad®). In order to demonstrate the interplay between dissolu-
tion and permeation, a simpliﬁed model was constructed, where the
dissolution rate was restricted on purpose and depletion in the donor
chamber was monitored (Sironi et al., 2017a). Sironi et al. concluded
that a substantial (> 10-fold) increase of the permeation area per donor
volume ratio is needed to achieve a substantial decrease in donor
concentration within a reasonable period of time. However, none of the
setups described in literature have a donor (dissolution) chamber con-
nected to a permeation barrier with a suﬃciently high area available
for absorption so that the permeation area to donor volume ratio is in
the order of magnitude as described by Sironi and co-workers.
5. The usefulness of cell-free permeation tools in non-oral drug
delivery studies
Since diﬀerent tissues in the human body have diﬀerent lipid
compositions, and as the lipid composition in the cell-free permeation
systems can easily be modiﬁed, several research groups have explored
the ability of these permeation systems to investigate drug delivery via
non-oral routes. Below, the implementation of the previously men-
tioned permeation tools in blood-brain barrier, transdermal, and buccal
delivery is brieﬂy discussed and schematically illustrated in Fig. 8.
5.1. Blood-brain barrier permeability
The blood-brain barrier is known as a highly selective barrier where
the paracellular transport is negligible but uptake and/or eﬄux trans-
porters aﬀect permeation of drugs more dramatically as compared to
the gastrointestinal tract. By adjusting the lipid composition of the
original PAMPA intended to evaluate gastrointestinal drug permeation,
a blood-brain barrier speciﬁc PAMPA (PAMPA-BBB) using porcine
brain lipid extract (PBLE; 20mg/mL) in n-dodecane was proposed (Di
et al., 2003). PBLE consists of phosphatidylethanolamine (33.1%),
phosphatidylserine (18.5%), phosphatidylcholine (12.6%), phospha-
tidic acid (0.8%) and phosphatidylinositol (4.1) supplemented with
cerebrosides, sulfatides and pigments. In this study, only drugs that are
substrates for active uptake and eﬄux transporters were misclassiﬁed
Fig. 7. Schematic illustration of (A) a microdialysis-dissolution-permeation system and (B) a two-stage dissolution test combined with a permeation compartment to
evaluate dissolution and permeation simultaneously.
Fig. 8. Overview of the applications of the diﬀerent cell-free permeation sys-
tems in (non)-oral drug delivery.
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while, classiﬁcation of passively transported drugs was correct for a set
of 25 compounds (Di et al., 2003). Also Mensch and co-workers ob-
served that PAMPA-BBB enabled to accurately predict blood-brain
barrier permeability for 19 structurally diverse, commercially available
drugs, except for caﬀeine and verapamil which are known as substrates
of an uptake and eﬄux transporter, respectively. Nevertheless, in
combination with a model covering active uptake and/or eﬄux such as
the Caco-2 assay, this PAMPA assay is highly useful as a ﬁrst method to
discard molecules with a low ability to cross the blood-brain barrier
(Mensch et al., 2010).
5.2. Transdermal delivery
Most of the artiﬁcial models used to mimic healthy, and to lesser
extent compromised skin, are relying either on phospholipid mixture
models or various types of diﬀusion cells. Several attempts have been
made to develop (i) chromatographic methods, (ii) non-lipid based
models like the silicone membranes (Ottaviani et al., 2006), and (iii)
lipid based models like PVPA and PAMPA as simple alternative models
for predicting dermal absorption (Flaten et al., 2015).
Sinko et al. reported the development of the skin-PAMPA consisting
of synthetic certramides, together with cholesterol, stearic acid and
silicon oil (Sinkó et al., 2009, 2012). The skin-PAMPA exhibited poor
correlation with skin epidermis; however, a good correlation with full
thickness skin was observed (Sinkó et al., 2012). The permeability data
of a selection of drugs solubilized in diﬀerent vehicles in the skin-
PAMPA model was compared with results from other artiﬁcial models
as well as porcine skin. The results demonstrated that the highest cor-
relation was observed for the skin-PAMPA, which ranked four out of six
vehicles correctly (Karadzovska and Riviere, 2013).
Originally, as thoroughly discussed above, PVPA was introduced as
a screening model for intestinal permeability, but by changing the lipid
composition of the liposomes used to produce the permeation barrier,
the PVPA model could be applied to predict transdermal absorption
(Engesland et al., 2013; Flaten et al., 2006b). The ﬁrst PVPA model
mimicking the stratum corneum barrier of the skin was introduced by
Engesland et al.; thereafter, several modiﬁed versions have been re-
leased (Engesland et al., 2013, 2015, 2016; Ma et al., 2017; Palac et al.,
2014; Zhang et al., 2017). In general, two main categories of the PVPA
model for estimating skin penetration have been presented: the simple
skin PVPA was prepared by liposomes of cholesterol and egg phos-
pholipids (Engesland et al., 2013; Zhang et al., 2017), while the more
complex skin PVPA contains all the main lipid classes that are present in
the skin including ceramide, cholesterol, free fatty acid, cholesteryl
sulfate, and egg phospholipids (Engesland et al., 2013; Ma et al., 2017).
Evaluation of transdermal permeation using these barriers is usually
performed in a 24 well plate format (Engesland et al., 2013, 2016; Palac
et al., 2014) or in a Franz diﬀusion cell setup (Ma et al., 2017; Zhang
et al., 2017). When comparing the permeability of a selection of drugs,
a similar ranking was observed between the simple or more complex
skin PVPA models on the one hand and animal skin penetration models
or calculated in silico values on the other hand (Engesland et al., 2013).
In addition, the complex skin PVPA was compared with the re-
constructed human EpiSkin® model. The complex skin PVPA demon-
strated the ability to distinguish between drug solutions and liposomal
formulations, and was superior to the EpiSkin® in terms of ease of use,
eﬃciency and cost-eﬀectiveness (Engesland et al., 2015). In another
study, Palac and co-workers used skin PVPA models to evaluate dif-
ferent liposome formulations containing diclofenac sodium, including
conventional liposomes, deformable liposomes and propylene glycol
liposomes (Palac et al., 2014). The permeation of the drug through the
PVPA barriers was clearly aﬀected by the lipid composition of the
formulation and increased, as expected, in the presence of penetration
enhancers (Palac et al., 2014). In addition, complex skin PVPA, con-
taining all the classes of lipids found in the stratum corneum, allowed to
explore the penetration enhancing eﬀect of menthol and the underlying
mechanism (Ma et al., 2017).
Lastly, the barrier function of the skin PVPA models could be
modiﬁed in a controlled manner allowing to investigate drug permea-
tion through compromised skin with reduced barrier functionality
(Engesland et al., 2013, 2016). Since these models have so far only been
used to test drugs in aqueous solutions, their potential use in for-
mulation optimization still needs to be evaluated.
5.3. Buccal delivery
Delivery of drugs through the buccal route is attractive because of
ease of access and patient compliance. The oral, in particular sub-
lingual, mucosa is well permeable because the epithelium is not kera-
tinized and no tight junctions are present. Since the buccal barriers are
well supplied with blood vessels whereby the drug molecules are di-
rectly released into the systemic circulation, this pathway beneﬁts from
circumventing harsh gastric and intestinal environments as well as ﬁrst
pass eﬀect connected to oral administration. Evaluation of buccal drugs
and formulations has classically been performed in vitro using cell-based
models (in many cases TR146 cell type from human cancer) or ex vivo
using animal tissues (e.g. from pig or rabbit, hamster pouch). Such
studies are widespread because these tissues are relatively easily
available. However, artiﬁcial membranes are attractive alternatives for
evaluation of buccal permeation in high throughput formats as com-
pared to cell-and tissue-based models as they are less laborious in
preparation and are expected to give a more reproducible outcome
since biological variation is excluded. Multiple studies describe the use
of ﬁlter (e.g. cellulose acetate, cellulose nitrate) (Delvadia et al., 2012;
Pongjanyakul and Suksri, 2009) and dialysis membranes (Dhiman et al.,
2008) to evaluate buccal permeation by comparing with ex vivo per-
meation through porcine buccal mucosa or an oral transmucosal in vivo
study. Khdair and co-workers reported that, using a variant of PAMPA
comprising cellulose acetate-nitrate ﬁlters and cellulose acetate ﬁlters
impregnated with L-phoSphatidylethanolamine in an octanol solution,
linear relationships between the permeation of carvedilol through this
artiﬁcial membrane and rabbit and porcine mucosa were observed
(Khdair et al., 2013). Using Permeapad® as buccal permeation barrier
with the same lipid composition as for the intestinal site, a recent study
discussed the direct comparison for formulations of diﬀerent pH values
of metoprolol with previously published in vitro, ex vivo and in vivo
studies. As such, permeability values obtained from Permeapad®
showed excellent correlation (Pearson correlation values> 0.97) with
in vitro TR146 cell culture and ex vivo porcine buccal mucosa in the
Ussing Chamber setup; in addition, data were in line with the absolute
bioavailability of metoprolol administered buccally to mini-pigs (Bibi
et al., 2016). Overall, these studies indicate that cell-free permeation
systems can be used to reliably predict buccal absorption in a faster and
less expensive way as compared to cell- and tissue-based systems or in
vivo studies.
6. Concluding remarks
During the past two decades, several artiﬁcial permeation models
have been developed for the prediction of the passive permeability of
various biological barriers. In addition to cutting costs of cell-and
tissue-based permeation tools, cell-free permeation models also proved
to be more robust against exogenous substances like pharmaceutical
excipients and/or food (digestion) components. As a result, these sys-
tems allow formulation scientists to simultaneously investigate dis-
solution of the formulation of interest and drug permeation without
compromising barrier integrity. While cell-free permeation systems
were initially intended to predict intestinal drug permeation, their
utility towards non-oral drug delivery including blood-brain barrier,
transdermal and buccal delivery was also demonstrated in recent years
by adjusting the composition of the permeation barrier.
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